Stocks Health care IBRX
NASDAQ · Health careImmunityBio, Inc. (IBRX)
ImmunityBio, Inc. brought in $165.8M of revenue over the twelve months to June 30, 2026, up 192.9% from a year earlier. It posted a net loss of $992.4M. In fiscal 2025 capital spending exceeded operating cash flow by $308.8M. At June 30, 2026 it held $75.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 4, 2026.
What ImmunityBio, Inc. does
ImmunityBio, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker IBRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $113.3M | -$351.4M | -$0.38 | -$308.8M |
| 2024 | $14.7M | -$413.6M | -$0.62 | -$398.1M |
| 2023 | $622K | -$583.2M | -$1.15 | -$397.3M |
| 2022 | $240K | -$416.6M | -$1.04 | -$415.7M |
| 2021 | $934K | -$346.8M | -$0.89 | -$308M |
| 2020 | $605K | -$221.9M | -$0.59 | -$173.4M |
Latest SEC filings
What ImmunityBio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 6, 2026Activist stake changed SCHEDULE 13D/A
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026
- August 4, 2026
- July 30, 2026
- June 10, 2026
- May 18, 2026
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026
- May 7, 2026
- April 30, 2026Additional proxy material DEFA14A
- April 30, 2026Proxy statement DEF 14A
Questions about IBRX
What does ImmunityBio, Inc. do?
ImmunityBio, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker IBRX.
Is ImmunityBio, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $992.4M on revenue of $165.8M.
How much revenue does ImmunityBio, Inc. make?
Over the twelve months to June 30, 2026 ImmunityBio, Inc. reported revenue of $165.8M. That is 192.9% more than a year earlier.
When did ImmunityBio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 4, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the activist stake changed from August 6, 2026.
Similar companies
Follow IBRX
Get an email when ImmunityBio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow IBRX: get an email when it filesWhere the numbers come from
Financial figures are the values ImmunityBio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.